{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:32Z","timestamp":1790391212170,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.critrevonc.2017.03.030","type":"journal-article","created":{"date-parts":[[2017,4,2]],"date-time":"2017-04-02T15:02:41Z","timestamp":1491145361000},"page":"13-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma \u2013 How far have we achieved?"],"prefix":"10.1016","volume":"114","author":[{"given":"Victor","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"To-Wai","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-On","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chung","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1385\/MO:21:3:211","article-title":"Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy","volume":"21","author":"Altundag","year":"2004","journal-title":"Med. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.03.030_bib0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/oxfordjournals.annonc.a058703","article-title":"A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma","volume":"5","author":"Au","year":"1994","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/A:1008255220284","article-title":"Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer","volume":"9","author":"Au","year":"1998","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0025","first-page":"222","article-title":"Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic\/recurrent undifferentiated carcinoma of the nasopharyngeal type","volume":"1","author":"Azli","year":"1995","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.critrevonc.2017.03.030_bib0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7150\/jca.2.341","article-title":"T cell therapy for nasopharyngeal carcinoma","volume":"2","author":"Basso","year":"2011","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","article-title":"Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and patients","volume":"64","author":"Baujat","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.03.030_bib0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2017.03.030_bib0045","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.1991.9.9.1675","article-title":"Chemotherapy of metastatic and\/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil","volume":"9","author":"Boussen","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ijc.2910420422","article-title":"Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas","volume":"42","author":"Busson","year":"1988","journal-title":"Int. J. Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2017.03.030_bib0055","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","article-title":"Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"23","author":"Chan","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2017.03.030_bib0060","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/ijc.23374","article-title":"Authentication of nasopharyngeal carcinoma tumor lines","volume":"122","author":"Chan","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2017.03.030_bib0065","doi-asserted-by":"crossref","first-page":"v187","DOI":"10.1093\/annonc\/mdq186","article-title":"Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Chan","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.03.030_bib0070","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ijrobp.2009.12.072","article-title":"Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma? Int","volume":"79","author":"Chan","year":"2011","journal-title":"J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.03.030_bib0075","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.oraloncology.2012.05.021","article-title":"Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy","volume":"48","author":"Chen","year":"2012","journal-title":"Oral. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0080","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-013-2196-8","article-title":"Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic\/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy","volume":"72","author":"Chen","year":"2013","journal-title":"Cancer. Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F","article-title":"Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus","volume":"83","author":"Cheung","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/1097-0142(19940115)73:2<247::AID-CNCR2820730203>3.0.CO;2-7","article-title":"A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma","volume":"73","author":"Chi","year":"1994","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0095","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-\u25b3LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2017.03.030_bib0105","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ejca.2007.03.022","article-title":"Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial","volume":"43","author":"Chitapanarux","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2017.03.030_bib0110","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1084\/jem.20072581","article-title":"An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival","volume":"205","author":"Choy","year":"2008","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.03.030_bib0115","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0959-8049(00)00008-3","article-title":"A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy","volume":"36","author":"Chua","year":"2000","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.1430","article-title":"Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma","volume":"94","author":"Chua","year":"2001","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1368-8375(02)00120-3","article-title":"A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy","volume":"39","author":"Chua","year":"2003","journal-title":"Oral Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.03.030_bib0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.oraloncology.2005.01.008","article-title":"A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma","volume":"41","author":"Chua","year":"2005","journal-title":"Oral Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jjco\/hyn022","article-title":"Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer","volume":"38","author":"Chua","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.03.030_bib0140","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hed.20792","article-title":"Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma","volume":"30","author":"Chua","year":"2008","journal-title":"Head Neck"},{"issue":"9","key":"10.1016\/j.critrevonc.2017.03.030_bib0145","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hed.21884","article-title":"Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer","volume":"34","author":"Chua","year":"2012","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0150","first-page":"161","article-title":"Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study","volume":"9","author":"Ciuleanu","year":"2004","journal-title":"J. BUON"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0155","first-page":"37","article-title":"Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study","volume":"13","author":"Ciuleanu","year":"2008","journal-title":"J. BUON"},{"issue":"35","key":"10.1016\/j.critrevonc.2017.03.030_bib0160","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.03.030_bib0165","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1200\/JCO.1995.13.6.1493","article-title":"Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer","volume":"13","author":"De Andr\u00e9s","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0170","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.7314\/APJCP.2012.13.5.2225","article-title":"Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients","volume":"13","author":"Dede","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0175","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.1993.11.1.70","article-title":"Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study","volume":"11","author":"Dugan","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2017.03.030_bib0180","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","article-title":"Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma","volume":"25","author":"Elser","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2017.03.030_bib0185","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0190","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/annonc\/mdf002","article-title":"Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type","volume":"13","author":"Foo","year":"2002","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2017.03.030_bib0195","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group Study","volume":"10","author":"Forastiere","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0385-8146(01)00135-3","article-title":"Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma","volume":"29","author":"Fujii","year":"2002","journal-title":"Auris Nasus Larynx"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0205","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.critrevonc.2015.01.008","article-title":"Metronomic chemotherapy from rationale to clinical studies: a dream or reality?","volume":"95","author":"Gnoni","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2017.03.030_bib0210","doi-asserted-by":"crossref","first-page":"769","DOI":"10.47102\/annals-acadmedsg.V37N9p769","article-title":"Association of Epstein-Barr virus with nasopharyngeal carcinoma and current status of development of cancer-derived cell lines","volume":"37","author":"Gullo","year":"2008","journal-title":"Ann. Acad. Med. Singapore"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0215","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1023\/A:1008342828496","article-title":"Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type","volume":"10","author":"Hasbini","year":"1999","journal-title":"Ann. Oncol."},{"issue":"Supplement 9","key":"10.1016\/j.critrevonc.2017.03.030_bib0220","doi-asserted-by":"crossref","first-page":"ix93","DOI":"10.1093\/annonc\/mdv527.02","article-title":"Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: interim results from a phase 1b study","volume":"26","author":"Hsu","year":"2015","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0225","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ijc.2910430535","article-title":"Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese","volume":"43","author":"Huang","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0230","first-page":"409","article-title":"Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma","volume":"21","author":"Huang","year":"2002","journal-title":"Ai. Zheng"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0235","first-page":"314","article-title":"Preliminary result of multicenter clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma","volume":"30","author":"Huang","year":"2008","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"10","key":"10.1016\/j.critrevonc.2017.03.030_bib0240","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.oraloncology.2012.04.003","article-title":"Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy","volume":"48","author":"Huang","year":"2012","journal-title":"Oral Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2017.03.030_bib0245","first-page":"2595","article-title":"Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival","volume":"8","author":"Hui","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0250","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cncr.20358","article-title":"Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group","volume":"101","author":"Hui","year":"2004","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.03.030_bib0255","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdq629","article-title":"Haemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation","volume":"22","author":"Hui","year":"2011","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.03.030_bib0260","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase 1 trial of recombinant modified vaccinia ankara (MVA) encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0265","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/1535-7163.MCT-12-0811","article-title":"Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus","volume":"12","author":"Hui","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.03.030_bib0270","first-page":"vi328","article-title":"Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation","volume":"27","author":"Hui","year":"2016","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0275","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ijrobp.2012.09.032","article-title":"Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment","volume":"85","author":"Jagdis","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.03.030_bib0280","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2407-6-178","article-title":"Trends in incidence and mortality of nasopharyngeal carcinoma over a 20\u201325 year period (1978\/1983\u20132002) in Sihui and Cangwu counties in southern China","volume":"6","author":"Jia","year":"2006","journal-title":"BMC Cancer"},{"issue":"December (6)","key":"10.1016\/j.critrevonc.2017.03.030_bib0285","first-page":"1158\/2326","article-title":"Bortezomib relieves immune tolerance in nasopharyngeal carcinoma via STAT1 suppression and indoleamine 2,3-dioxygenase downregulation","volume":"10","author":"Jiang","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0290","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.virusres.2005.07.010","article-title":"Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status","volume":"115","author":"Krishna","year":"2006","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0295","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7314\/APJCP.2013.14.2.1121","article-title":"Carboplatin\/5-fluorouracil as an alternative to Cisplatin\/5-fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma","volume":"14","author":"Kua","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0300","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ijrobp.2004.07.702","article-title":"Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience","volume":"61","author":"Lee","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0305","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.oraloncology.2009.12.007","article-title":"High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer","volume":"46","author":"Lee","year":"2010","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0310","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(11)70303-5","article-title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0315","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00005537-200401000-00029","article-title":"Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx","volume":"114","author":"Leong","year":"2004","journal-title":"Laryngoscope"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.03.030_bib0320","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.23687","article-title":"Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma","volume":"113","author":"Leong","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0325","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-007-0641-2","article-title":"Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma","volume":"62","author":"Li","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0330","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0b013e31828bd87b","article-title":"Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy","volume":"36","author":"Li","year":"2013","journal-title":"J. Immunother."},{"issue":"16","key":"10.1016\/j.critrevonc.2017.03.030_bib0335","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-10-3409","article-title":"A Phase II study of pazopanib in Asian patients with recurrent\/metastatic nasopharyngeal carcinoma","volume":"17","author":"Lim","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0340","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.oraloncology.2012.12.012","article-title":"A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma","volume":"49","author":"Lim","year":"2013","journal-title":"Oral Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2017.03.030_bib0345","first-page":"6952","article-title":"Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0350","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2013.01.052","article-title":"Role of MIF\/CXCL8\/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres","volume":"335","author":"Lo","year":"2013","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0355","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1008215213739","article-title":"Carboplatin versus cisplatin in solid tumours: an analysis of the literature","volume":"9","author":"Lokich","year":"1998","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.03.030_bib0360","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood-2008-05-157222","article-title":"Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients","volume":"113","author":"Louis","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2017.03.030_bib0365","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0370","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cncr.20768","article-title":"Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma","volume":"103","author":"Ma","year":"2005","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2017.03.030_bib0375","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/cncr.10995","article-title":"Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma","volume":"95","author":"Ma","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0380","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00280-007-0575-8","article-title":"A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy","volume":"62","author":"Ma","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.03.030_bib0385","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdp065","article-title":"Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma\u2013correlation with excision repair cross-complementing-1 polymorphisms","volume":"20","author":"Ma","year":"2009","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0390","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10637-012-9896-5","article-title":"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines","volume":"31","author":"Ma","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0395","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10637-015-0264-0","article-title":"Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)","volume":"33","author":"Ma","year":"2015","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.critrevonc.2017.03.030_bib0400","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1368-8375(01)00134-8","article-title":"A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"38","author":"McCarthy","year":"2002","journal-title":"Oral. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2017.03.030_bib0405","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/annonc\/mdf200","article-title":"Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study","volume":"13","author":"Ngan","year":"2002","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0410","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/annonc\/mdq425","article-title":"Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma","volume":"22","author":"Ngeow","year":"2011","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.03.030_bib0415","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0959-8049(03)00310-1","article-title":"Design of a prognostic index score for metastatic nasopharyngeal carcinoma","volume":"39","author":"Ong","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0420","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0425","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ijc.20711","article-title":"Frequent genetic and biochemical alterations of the PI3-K\/AKT\/PTEN pathway in head and neck squamous cell carcinoma","volume":"114","author":"Pedrero","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0430","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/cncr.20802","article-title":"Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma","volume":"103","author":"Poon","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0435","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000119925","article-title":"Antiangiogenic metronomic chemotherapy","volume":"31","author":"Sarmiento","year":"2008","journal-title":"Onkologie"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0440","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/annonc\/mdr134","article-title":"T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results","volume":"23","author":"Secondino","year":"2012","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.03.030_bib0445","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.03.030_bib0450","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1073\/pnas.0801130105","article-title":"MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins","volume":"105","author":"Sengupta","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.critrevonc.2017.03.030_bib0455","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1349-7006.1999.tb00710.x","article-title":"Epstein-Barr virus-encoded latent membrane protein 1 coexpresses with epidermal growth factor receptor in nasopharyngeal carcinoma","volume":"90","author":"Sheen","year":"1999","journal-title":"Jpn. J. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2017.03.030_bib0460","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/ijc.24880","article-title":"Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer","volume":"126","author":"Shi","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2017.03.030_bib0465","first-page":"149","article-title":"Efficacy of 4-epidoxorubicin in advanced nasopharyngeal carcinoma","volume":"26","author":"Shiu","year":"1989","journal-title":"Clin. Trials J."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.03.030_bib0470","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.1998.16.7.2514","article-title":"Phase I\/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx","volume":"16","author":"Siu","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0475","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","article-title":"Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy","volume":"72","author":"Smith","year":"2012","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0480","doi-asserted-by":"crossref","first-page":"e1273311","DOI":"10.1080\/2162402X.2016.1273311","article-title":"Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotypic and effector function of T cells impact on clinical response","volume":"6","author":"Smith","year":"2017","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0485","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00000421-199608000-00014","article-title":"A phase II study of cisplatin\/ifosfamide in recurrent\/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa","volume":"19","author":"Stein","year":"1996","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.03.030_bib0490","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","article-title":"Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0495","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000227179","article-title":"Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan","volume":"50","author":"Su","year":"1993","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0500","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2010.02.061","article-title":"Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy","volume":"80","author":"Sun","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.03.030_bib0505","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.03.030_bib0510","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1101::AID-CNCR2>3.0.CO;2-R","article-title":"Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type","volume":"86","author":"Taamma","year":"1999","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0515","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1023\/A:1008390929826","article-title":"Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma","volume":"10","author":"Tan","year":"1999","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0520","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","article-title":"Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma","volume":"91","author":"Tan","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"14","key":"10.1016\/j.critrevonc.2017.03.030_bib0525","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1128\/JVI.00613-16","article-title":"NF-(B signaling regulates expression of Epstein-Barr virus BART microRNAs and long noncoding RNAs in nasopharyngeal carcinoma","volume":"90","author":"Verhoeven","year":"2016","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.03.030_bib0530","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancers","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0535","first-page":"601","article-title":"Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma","volume":"20","author":"Wang","year":"1991","journal-title":"Ann. Acad. Med. Singapore"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0540","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hed.20310","article-title":"Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma","volume":"28","author":"Wang","year":"2006","journal-title":"Head Neck"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0545","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.oraloncology.2007.06.004","article-title":"Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma","volume":"44","author":"Wang","year":"2008","journal-title":"Oral Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0550","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2005-07-2702","article-title":"Epstein-Barr virus: the impact of scientific advances on clinical practice","volume":"107","author":"Williams","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2017.03.030_bib0555","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1245\/s10434-008-0001-4","article-title":"Does surgical resection of pulmonary metastases of head and neck cancer improve survival?","volume":"15","author":"Winter","year":"2008","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0560","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bbrc.2009.11.093","article-title":"miR-200a-mediated downregulation of ZEB 2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion","volume":"391","author":"Xia","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.03.030_bib0565","first-page":"658","article-title":"Expression and significance of PTEN in nasopharyngeal carcinoma","volume":"18","author":"Xu","year":"2004","journal-title":"Lin Chuang Er Bi Yan Hou Ke Za Zhi"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0570","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/annonc\/mds581","article-title":"Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma","volume":"24","author":"Xue","year":"2013","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0575","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ijrobp.2006.06.016","article-title":"Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes","volume":"66","author":"Yau","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0580","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.oraloncology.2011.12.001","article-title":"A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"48","author":"Yau","year":"2012","journal-title":"Oral Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.03.030_bib0585","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s002800050512","article-title":"Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma","volume":"38","author":"Yeo","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"13","key":"10.1016\/j.critrevonc.2017.03.030_bib0590","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0959-8049(98)00280-9","article-title":"A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma","volume":"34","author":"Yeo","year":"1998","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.03.030_bib0595","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/COC.0b013e31820dbdcc","article-title":"A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and\/or metastatic nasopharyngeal carcinoma","volume":"35","author":"You","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.03.030_bib0600","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00280-007-0441-8","article-title":"Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy","volume":"61","author":"Zhang","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.03.030_bib0605","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/carcin\/bgp335","article-title":"microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network","volume":"31","author":"Zhang","year":"2010","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.03.030_bib0610","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/carcin\/bgs346","article-title":"MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN","volume":"34","author":"Zhang","year":"2013","journal-title":"Carcinogenesis"},{"issue":"10054","key":"10.1016\/j.critrevonc.2017.03.030_bib0615","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"issue":"40","key":"10.1016\/j.critrevonc.2017.03.030_bib0620","doi-asserted-by":"crossref","first-page":"11283","DOI":"10.1073\/pnas.1607606113","article-title":"Whole-exome sequencing identifies multiple loss-of-function mutations of NF-(B pathway regulators in nasopharyngeal carcinoma","volume":"113","author":"Zheng","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281630405X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281630405X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T11:30:11Z","timestamp":1719142211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281630405X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":124,"alternative-id":["S104084281630405X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.030","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma \u2013 How far have we achieved?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}